Brief: Contineum Therapeutics Reports Positive Topline Phase 1b PET Data for PIPE-791
18/09/2025 13:27
Sept 18 (Reuters) - Contineum Therapeutics Inc CTNM.O: CONTINEUM THERAPEUTICS REPORTS POSITIVE TOPLINE DATA FROM PHASE 1B POSITRON EMISSION TOMOGRAPHY (PET) TRIAL OF PIPE-791 CONTINEUM THERAPEUTICS INC - PIPE-791 ACHIEVES HIGH BRAIN RECEPTOR OCCUPANCY CONTINEUM THERAPEUTICS INC - PIPE-791 SHOWS CONSISTENT SAFETY AND TOLERABILITY PROFILE Source text: ID:nBw8CCtNZa Further company coverage: CTNM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Contineum Therapeutics
See all newsPREVIEW: Johnson & Johnson earnings expected to decline in Q3
PREVIEW: Johnson & Johnson earnings expected to decline in Q3
US STOCKS ON THE MOVE-Microsoft, Salesforce, Bristol Myers
US STOCKS ON THE MOVE-Microsoft, C3.ai, Salesforce, Bristol Myers
Contineum tumbles as Bristol's partial trial win raises dose doubts